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SUMMARY
1. The serotonin1A receptors are members of a superfamily of seven transmembrane
domain receptors that couple to G-proteins, and appear to be involved in several behav-
ioral and cognitive functions.
2. We monitored the effect of prolonged treatment of the human serotonin1A
receptor expressed in Chinese hamster ovary (CHO) cells with pharmacologi-
cally well-characterized ligands on its binding to the agonist 8-hydroxy-2(di-N-
propylamino)tetralin (8-OH-DPAT) and antagonist 4-(2′-methoxy)-phenyl-1-[2′-(N-2′′-
pyridinyl)-p-fluorodobenzamido]ethyl-piperazine (p-MPPF).
3. Our results indicate that prolonged treatment with the specific agonist (8-OH-
DPAT) differentially affects subsequent binding of the agonist and antagonist to the
receptor in a manner independent of receptor-G-protein coupling. Importantly, our re-
sults show that prolonged treatment with the commonly used antagonist p-MPPF, and its
iodinated analogue 4-(2′-methoxy)-phenyl-1-[2′-(N-2′′-pyridinyl)-p-iodobenzamido]ethyl-
piperazine (p-MPPI), which have earlier been reported to display similar binding proper-
ties to serotonin1A receptors, induces significantly different effects on the ligand binding
function of serotonin1A receptors.
KEY WORDS: serotonin1A receptor; agonist; antagonist; inverse agonist; G-protein cou-
pling; desensitization.
INTRODUCTION
Serotonin (5-hydroxytryptamine or 5-HT) acts as a neurotransmitter and is found
in a wide variety of sites in the central and peripheral nervous systems (Jacobs and
Azmitia, 1992). Serotonergic signaling appears to play a key role in the generation
and modulation of various cognitive and behavioral functions such as sleep, mood,
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pain, addiction, locomotion, sexual activity, depression, anxiety, alcohol abuse, ag-
gression and learning (Artigas et al., 1996; Ramboz et al., 1998; Rocha et al., 1998;
Meneses, 1999; Gross et al., 2002; Adayev et al., 2005). Disruptions in serotonergic
systems have been implicated in the etiology of mental disorders such as schizophre-
nia, migraine, depression, suicidal behavior, infantile autism, eating disorders, and
obsessive-compulsive disorder (Ramboz et al., 1998; Heisler et al., 1998; Parks et al.,
1998; Sarnyai et al., 2000). The G-protein coupled serotonin1A receptor subtype rep-
resents the most well studied member among the subtypes of serotonin receptors
(Raymond et al., 1999; Pucadyil et al., 2005), and its functional significance is appar-
ent from the enhanced anxiety-related behavior exhibited by knockout mice lacking
the receptor (Ramboz et al., 1998; Heisler et al., 1998; Parks et al., 1998). As a re-
sult, these mice represent important animal models for the analysis of complex traits
such as anxiety and aggression in higher organisms (Gingrich and Hen, 2001).
Desensitization is a phenomenon whereby receptors exhibit reduction or loss
of response upon prolonged activation by ligands, thereby acting as a feedback
mechanism in terminating the cellular response generated by a prolonged stim-
ulus (Ochoa et al., 1989; Lohse, 1993; Gainetdinov et al., 2004). The desensitiza-
tion of serotonin1A receptors assumes significance due to the role of this receptor
in neuronal physiology, and its involvement in the action of a variety of clinically
prescribed drugs. Long-term treatment with serotonin1A receptor agonists and an-
tagonists constitutes a powerful therapeutic approach in anxiety- or stress-related
disorders (Blier et al., 1990; Griebel, 1999), and in developmental disorders (Azmi-
tia, 2001). Further, several antidepressants increase the concentration of serotonin
present in synapses by blocking serotonin transporters and autoreceptors leading to
prolonged exposure of the receptor to serotonin (Hensler, 2003). The analysis of the
effect of prolonged ligand exposure on the serotonin1A receptor function therefore
assumes importance. This forms the basis of earlier reports which have analyzed the
effect of long-term treatment with agonist and antagonist on the serotonin1A recep-
tor ligand binding and signaling (Harrington et al., 1994; Hensler et al., 1996; Cowen
et al., 1997; Hensler and Durgam, 2001; Hensler, 2003). While these studies have
provided valuable insight into the possible mechanisms on the desensitization of the
serotonin1A receptor upon long-term treatment with ligands, analysis of the relative
binding ability of the serotonin1A receptors in the same cell type after prolonged
ligand treatment to specific agonist and antagonist remains unexplored.
In this paper, we monitored the effect of prolonged treatment of the human
serotonin1A receptor heterologously expressed in Chinese hamster ovary (CHO)
cells to pharmacologically well-characterized agonist and antagonists specific for
the serotonin1A receptor. Importantly, our results indicate that treatment with the
specific agonist (8-OH-DPAT) differentially affects subsequent binding of the ag-
onist 8-OH-DPAT and antagonist p-MPPF to the receptor in a manner indepen-
dent of receptor-G-protein coupling. More importantly, our results show that pro-
longed treatment with the commonly used antagonist p-MPPF, and its iodinated
analogue p-MPPI, which have earlier been reported to display similar binding prop-
erties (Thielen et al., 1996; Barr and Manning, 1997; Kalipatnapu et al., 2004) and
antagonize the action of serotonin1A receptor specific agonists in animal models
(Thielen and Frazer, 1995; Thielen et al., 1996), induces significantly different ef-
fects on ligand binding to serotonin1A receptors.
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MATERIALS AND METHODS
Materials
Fetal calf serum, 8-OH-DPAT, p-MPPI, p-MPPF, penicillin, streptomycin, gen-
tamycin sulfate, phenylmethylsulfonyl fluoride (PMSF), serotonin and polyethylen-
imine were obtained from Sigma Chemical Co. (St. Louis, MO). D-MEM/F-12
(Dulbecco’s Modified Eagle Medium: nutrient mixture F-12 (Ham) (1:1)) and ge-
neticin (G 418) were from Life Technologies (Grand Island, NY). Guanosine-5′-
O-(3-thiotriphosphate) (GTP-γ-S) was from Roche Applied Science (Mannheim,
Germany). Bicinchoninic acid (BCA) reagent kit for protein estimation was from
Pierce (Rockford, IL). [3H]8-OH-DPAT (sp. activity = 135.0 Ci/mmol) and [3H]p-
MPPF (sp. activity = 70.5 Ci/mmol) were purchased from DuPont New England
Nuclear (Boston, MA). GF/B glass microfiber filters were obtained from Whatman
International (Kent, UK). All other chemicals used were of the highest purity avail-
able. Water was purified through a Millipore (Bedford, MA) Milli-Q system and
used throughout.
Cell Culture and Prolonged Ligand Treatment of Serotonin1A Receptors
CHO cells stably expressing the human serotonin1A receptor have been de-
scribed earlier (Kalipatnapu et al., 2004). These cells were maintained in D-MEM/F-
12 (1:1) supplemented with 2.4 g/L of sodium bicarbonate, 10% fetal calf serum,
60 µg/mL penicillin, 50 µg/mL streptomycin, 50 µg/mL gentamycin sulfate, and
200 µg/mL geneticin in a humidified atmosphere with 5% CO2 at 37◦C. Prolonged
treatment of the human serotonin1A receptor expressed in these cells with receptor-
specific ligands was carried out by incubating cells for 18 h in medium contain-
ing either 8-OH-DPAT (10 µM), p-MPPF (1 µM), or p-MPPI (1 µM). Following
this treatment, cells were rinsed with PBS and harvested for preparation of cell
membranes.
Preparation of Cell Membranes
Cell membranes were prepared as described previously (Kalipatnapu et al.,
2004). Confluent cells were harvested by treatment with ice-cold buffer contain-
ing 10 mM Tris, 5 mM EDTA, 0.1 mM PMSF, pH 7.4. Cells were then homog-
enized for 10 s at 4◦C at maximum speed with a Polytron homogenizer. The cell
lysate was centrifuged at 500 × g for 10 min at 4◦C and the resulting post-nuclear
supernatant was centrifuged at 40,000 × g for 30 min at 4◦C. The pellet thus ob-
tained (cell membranes) was suspended in 50 mM Tris buffer, pH 7.4. Total protein
concentration in cell membranes was determined using BCA reagent (Smith et al.,
1985).
Radioligand Binding Assays
Receptor binding assays were carried out as described earlier (Kalipatnapu
et al., 2004). Briefly, tubes in duplicate containing cell membranes were incubated
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in a total volume of 1 mL of buffer A (50 mM Tris, 1 mM EDTA, 10 mM MgCl2,
5 mM MnCl2, pH 7.4) for agonist binding assays, or in 1 mL of buffer B (50 mM
Tris, 1 mM EDTA, pH 7.4) for antagonist binding assays. Tubes were incubated
with the radiolabeled agonist [3H]8-OH-DPAT (final concentration = 0.29 nM) or
antagonist [3H]p-MPPF (final concentration = 0.5 nM) for 1 h at room tempera-
ture (25◦C). Non-specific binding was determined by performing the assay either
in the presence of 10 µM serotonin (for agonist binding assays) or in the presence
of 10 µM p-MPPI (for antagonist binding assays). The binding reaction was termi-
nated by rapid filtration under vacuum in a Brandel cell harvester (Gaithersburg,
MD) through Whatman GF/B 2.5 cm diameter glass microfiber filters (1.0 µm pore
size) which were presoaked in 0.15% (w/v) polyethylenimine for 1 h (Bruns et al.,
1983). The filters were then washed three times with 3 mL of cold water (4◦C), dried
and the retained radioactivity was measured in a Packard Tri-Carb 1500 liquid scin-
tillation counter using 5 mL of scintillation fluid.
GTP-γ-S Sensitivity Assay
Agonist binding assays were carried out in buffer A as described above in the
presence of varying concentrations of GTP-γ-S as described previously (Harikumar
and Chattopadhyay, 1999; Kalipatnapu et al., 2004). The concentrations of GTP-
γ-S leading to 50% inhibition of specific agonist binding (IC50) were calculated by
non-linear regression fitting of the data to a four parameter logistic function:
B = a[1 + (x/I)S]−1 + b (1)
where B is the specific binding of the agonist normalized to control binding (in the
absence of GTP-γ-S), x denotes concentration of GTP-γ-S, a is the range (ymax–
ymin) of the fitted curve on the ordinate (y-axis), I is the IC50 concentration, b is the
background of the fitted curve (ymin) and S is the slope factor.
RESULTS AND DISCUSSION
Chinese hamster ovary cells have previously been used to understand several
pharmacological and signaling aspects of the serotonin1A receptor (Raymond
et al., 1999). We have earlier characterized CHO cells stably expressing the human
serotonin1A receptor (Kalipatnapu et al., 2004). The expression of the serotonin1A
receptor in these cells is under the control of the Rous Sarcoma virus (RSV) long
terminal repeat (Banerjee et al., 1993), and the pharmacology and cellular signaling
characteristics of the receptor have been shown to be essentially similar to the
native hippocampal serotonin1A receptor (Banerjee et al., 1993; Kalipatnapu et al.,
2004). Importantly, the radiolabeled agonist [3H]8-OH-DPAT displays a maximum
number of binding sites (Bmax) of 1.24 pmol/mg protein while the radiolabeled
antagonist [3H]p-MPPF displays a Bmax of 3.93 pmol/mg protein in membranes
isolated from these cells (Kalipatnapu et al., 2004). This difference is attributed to
the agonist 8-OH-DPAT preferentially binding to the G-protein coupled form of
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the receptor while the antagonist p-MPPF binding equally well to the G-protein
coupled and uncoupled forms of the receptor.
As a paradigm to understand desensitization processes involving the
serotonin1A receptor, we analyzed the effect of prolonged exposure of ligands to
CHO cells stably expressing the serotonin1A receptor on the ligand binding function
of the receptor. The development of selective serotonin1A agonist (8-OH-DPAT)
and antagonists (p-MPPI and p-MPPF), which bind serotonin1A receptors with high
affinity and specificity, has contributed to our understanding of the pharmacology
and signaling functions of the receptor (Gozlan et al., 1983; Thielen et al., 1996; Barr
and Manning, 1997; Harikumar and Chattopadhyay, 1999). We analyzed the effect
of prolonged (18 h) treatment of cells with 8-OH-DPAT and p-MPPF on specific ag-
onist [3H]8-OH-DPAT binding to membranes isolated from these cells. Prolonged
treatment with 8-OH-DPAT leads to a significant reduction in specific binding of
[3H]8-OH-DPAT to isolated cell membranes (Fig. 1A). Thus, membranes isolated
from 8-OH-DPAT-treated cells show ∼46% reduction in binding of [3H]8-OH-
DPAT compared to those isolated from control cells. Interestingly, similar analysis
carried out with membranes isolated from cells treated with p-MPPF does not show
a significant effect on specific [3H]8-OH-DPAT binding (Fig. 1A).
Because agonists such as 8-OH-DPAT bind to receptors coupled to G-proteins,
whereas antagonists like p-MPPF bind to both G-protein coupled and uncoupled
forms of the receptor (Harikumar and Chattopadhyay, 1999; Javadekar-Subhedar
and Chattopadhyay, 2004; Pucadyil et al., 2005), their relative binding abilities can
be used to differentially discriminate the extent of interaction between the receptor
and G-proteins. To analyze the effect of prolonged ligand treatment on the total
(G-protein coupled and uncoupled) serotonin1A receptor population, we monitored
binding of the specific antagonist [3H]p-MPPF under such conditions. As shown in
Fig. 1B, specific [3H]p-MPPF binding does not appear to be significantly different
in membranes isolated from cells treated with either 8-OH-DPAT or p-MPPF. In
fact, prolonged treatment with 8-OH-DPAT appears to induce a moderate (∼23%)
increase in specific [3H]p-MPPF binding (Fig. 1B).
The analysis of receptor ligand binding upon prolonged treatment of cells with
specific ligands can be complicated due to the possible effects on cellular biosynthe-
sis of receptors. Thus, any effect on ligand binding of the receptor can be interpreted
to arise from changes either in the binding affinity of the ligand or in the total num-
ber of receptors expressed in cells. On the basis of our results where prolonged treat-
ment of cells does not appear to significantly affect specific [3H]p-MPPF binding
(which reflects the total population of serotonin1A receptors), the effect of agonist
treatment on the binding of [3H]8-OH-DPAT (Fig. 1A) could reflect desensitiza-
tion of serotonin1A receptors by a mechanism that does not involve downregulation
of receptor biosynthesis. Moreover, the trivial possibility of reduction in specific
[3H]8-OH-DPAT binding observed when cells are treated with 8-OH-DPAT (Fig.
1A) due to competition between the labeled and unlabeled forms of 8-OH-DPAT
can be ruled out because such competition would have led to a reduction in specific
binding of [3H]p-MPPF as well, which is not the case (Fig. 1B).
Interestingly, there appears to be a lack of consensus in previous literature
on the effect of prolonged agonist treatment on the binding of [3H]8-OH-DPAT
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Fig. 1. Specific binding of the (A) agonist [3H]8-OH-DPAT and
(B) antagonist [3H]p-MPPF to membranes isolated from CHO
cells stably expressing the human serotonin1A receptor that were
treated with either the agonist 8-OH-DPAT (10 µM), or the an-
tagonist p-MPPF (1 µM) for 18 h. Values are expressed as per-
centages of specific radioligand binding obtained in membranes
isolated from untreated cells (control). The data shown are the
means ± SE of duplicate points from at least six independent ex-
periments. See Materials and Methods section for other details.
to serotonin1A receptors. While long-term treatment of serotonin1A receptors ex-
pressed in HeLa cells with 8-OH-DPAT has been found to result in a loss of high-
affinity agonist binding sites (Harrington et al., 1994), another study with the agonist
5-carboxamidotryptamine (5-CT) showed no significant effect on binding of [3H]8-
OH-DPAT to serotonin1A receptors expressed in P11 cells (Hensler et al., 1996).
In this context, our analysis of the effect of prolonged treatment with 8-OH-DPAT
and p-MPPF on binding of both the agonist [3H]8-OH-DPAT and the antagonist
[3H]p-MPPF to serotonin1A receptors assumes relevance.
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Desensitization of serotonin1A receptors upon prolonged treatment with ago-
nists has earlier been speculated to occur due to alterations in receptor-G-protein
coupling (Hensler and Durgam, 2001) that possibly leads to a reduction in the abil-
ity of the receptor to affect downstream signaling events (Harrington et al., 1994).
The serotonin1A receptor agonists are known to specifically activate the Gi/Go class
of G-proteins (Raymond et al., 1999). Therefore, agonist binding to such receptors
displays sensitivity to agents that uncouple the normal cycle of guanine nucleotide
exchange at the G-protein α subunit (such as GTP-γ-S, a non-hydrolyzable ana-
logue of GTP) caused by activation of the receptor. We find that treatment of cells
with 8-OH-DPAT leads to a reduction in specific agonist [3H]8-OH-DPAT bind-
ing to cell membranes, whereas specific antagonist [3H]p-MPPF binding displays
a moderate increase (Fig. 1). We analyzed if the reduction in specific binding of
[3H]8-OH-DPAT upon prolonged treatment of cells with 8-OH-DPAT is due to
a reduction in G-protein coupling of the serotonin1A receptor by monitoring the
sensitivity of agonist binding to GTP-γ-S (Harikumar and Chattopadhyay, 1999).
Figure 2 shows the inhibition of specific [3H]8-OH-DPAT binding to serotonin1A
receptors in the presence of GTP-γ-S in a characteristic concentration-dependent
manner in membranes isolated from control and 8-OH-DPAT-treated cells. The
half maximal inhibition concentration (IC50) value for inhibition of specific [3H]8-
OH-DPAT binding by GTP-γ-S is ∼3.3 nM for membranes isolated from control
cells, similar to what we reported earlier (Kalipatnapu et al., 2004). Interestingly,
Fig. 2. Effect of increasing concentrations of GTP-γ-S on spe-
cific [3H]8-OH-DPAT binding to human serotonin1A receptors
in membranes isolated from control (— ◦ —) and 8-OH-DPAT-
treated (—•—) cells. The conditions for 8-OH-DPAT treatment
are as described in Fig. 1. Values are expressed as percentages of
the specific [3H]8-OH-DPAT binding obtained in the absence of
GTP-γ-S. The curves are non-linear regression fits to the exper-
imental data using Eq. (1). Data represent the means ± SE of
duplicate points from five independent experiments. See Materi-
als and Methods section for other details.
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the extent of inhibition in [3H]8-OH-DPAT binding to membranes isolated from
8-OH-DPAT-treated cells by GTP-γ-S does not appear to be significantly different
(IC50 value of ∼3.8 nM). On the basis of the sensitivity of [3H]8-OH-DPAT bind-
ing to serotonin1A receptors to GTP-γ-S, we conclude that G-protein coupling of
the receptor does not display any significant change upon prolonged treatment with
the agonist 8-OH-DPAT. Our results therefore suggest the possibility of an alter-
nate mechanism for the observed loss in [3H]8-OH-DPAT binding to membranes
isolated from 8-OH-DPAT-treated cells.
Earlier reports have described that the binding parameters of p-MPPI to
serotonin1A receptors appear to be similar to that of p-MPPF (Thielen et al., 1996;
Barr and Manning, 1997; Kalipatnapu et al., 2004). Moreover, these two ligands have
earlier been found to antagonize the response generated upon in vivo administration
of the serotonin1A receptor specific agonist 8-OH-DPAT in animal models (Thielen
and Frazer, 1995). Interestingly, based on the ability of ligands to reduce constitutive
activity of serotonin1A receptors expressed in Spodoptera frugiperda cells, p-MPPF
has been categorized as a neutral antagonist, whereas p-MPPI has been shown to
display partial inverse agonist activity on serotonin1A receptors (Barr and Manning,
1997). To analyze if p-MPPI indeed differs from p-MPPF from the perspective of de-
sensitization of serotonin1A receptors, we monitored the effect of prolonged treat-
ment with p-MPPI on ligand binding ability of serotonin1A receptors. As shown in
Fig. 3, ligand binding to serotonin1A receptors in membranes isolated from cells
treated with p-MPPI for 18 h show a dramatically different result compared to what
Fig. 3. Specific binding of the agonist [3H]8-OH-DPAT (white
bars) and antagonist [3H]p-MPPF (gray bars) to membranes iso-
lated from CHO cells stably expressing the human serotonin1A re-
ceptor that were treated with p-MPPI (1 µM) for 18 h. Values are
expressed as percentages of specific radioligand binding obtained
in membranes isolated from untreated cells (control). Data rep-
resent the means ± SE of duplicate points from at least six inde-
pendent experiments. See Materials and Methods section for other
details.
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was observed when cells were treated with the antagonist p-MPPF (Fig. 1). Thus,
membranes isolated from p-MPPI-treated cells display a marked (>80%) reduc-
tion in specific binding of the agonist [3H]8-OH-DPAT and antagonist [3H]p-MPPF
(Fig. 3). To the best of our knowledge, this is the first report describing the ef-
fect of prolonged treatment of serotonin1A receptors to p-MPPI in terms of bind-
ing of the specific agonist [3H]8-OH-DPAT and antagonist [3H]p-MPPF. An ear-
lier report, which monitored serotonin1A receptor function by analyzing binding of
[125I]p-MPPI, described an upregulation in serotonin1A receptor number in CHO
cells after long-term exposure of cells to p-MPPI (Cowen et al., 1997). This increase
in receptor number was attributed to an increase in transcriptional activity of the
cytomegalovirus (CMV) promoter that regulated expression of the serotonin1A re-
ceptor in these cells. On the basis of the criteria of specific binding of the classical
agonist [3H]8-OH-DPAT and antagonist [3H]p-MPPF, our results show a contrary
trend. Importantly, our results on the reduction in ligand binding to serotonin1A re-
ceptors upon p-MPPI treatment (Fig. 3) bring out a previously unappreciated differ-
ence in the long-term action of the antagonists p-MPPF, and its iodinated analogue
p-MPPI. In light of the widespread use of p-MPPI and p-MPPF as an antagonist to
serotonin1A receptor function in animal models (Thielen and Frazer, 1995; Theilen
et al., 1996; Teng et al., 2003), our results suggest a more detailed analysis of the
pharmacology of p-MPPF, and its iodinated analogue p-MPPI before their antago-
nist properties on the serotonin1A receptor can be assumed in animal studies.
In summary, we show that prolonged treatment of serotonin1A receptors in a
cellular environment to specific ligands induces significant effects on ligand binding
of the receptor that are specific to the type of ligand used. We observe a reduction
in specific binding of the agonist [3H]8-OH-DPAT but not the antagonist [3H]p-
MPPF upon prolonged treatment with the agonist 8-OH-DPAT, in a manner that is
independent of receptor-G-protein coupling. Importantly, we find novel differences
in ligand binding to serotonin1A receptors in response to prolonged treatment with
the classical antagonist p-MPPF, and its iodinated analogue p-MPPI. As mentioned
earlier, long-term treatment with serotonin1A receptor agonists and antagonists con-
stitutes a powerful therapeutic approach in anxiety- or stress-related disorders, and
in developmental disorders (Blier et al., 1990; Griebel, 1999; Azmitia, 2001). While
the identification of the serotonin1A receptor as an important therapeutic target in
a variety of complex behavioral traits represents a significant step (Gingrich and
Hen, 2001), the success of therapeutic approaches that involve the administration
of ligands specific to the serotonin1A receptor depends on the long-term effect of
such treatments on the serotonin1A receptor function. Our analysis on ligand bind-
ing of serotonin1A receptors under conditions of prolonged treatment with ligands
represents an attempt in this direction.
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